Sansheng Pharmaceutical (01530) rose more than 7%. As of press release, it rose 7% to HK$5.81, with a turnover of HK$566.979 million.
The Zhitong Finance App learned that Sansheng Pharmaceutical (01530) rose by more than 7%. As of press release, it had risen 7% to HK$5.81, with a turnover of HK$56.9979 million.
According to the news, Sansheng Pharmaceutical announced that according to the 2023 repurchase authorization, the company was approved to repurchase up to about 244 million shares on the Hong Kong Stock Exchange Limited, accounting for 10% of the total number of shares issued on the date of the company's annual shareholders' meeting held on June 20, 2023. The proposed share repurchase reflects the company's affirmation of its own value and confidence in the long-term prospects of the industry.
In addition, Sansheng Pharmaceutical recently announced its 2023 annual results, with revenue of 7.816 billion yuan (RMB, same below), up 13.8% year on year; gross profit of 6.642 billion yuan, up 17.1% year on year; parent company owners should account for adjusted operating net profit of 1,952 billion yuan, up 17.7% year on year; and plans to pay a final dividend of HK25 cents per share. The increase in revenue during the reporting period was mainly due to strong sales growth in Turbie Australia and Mandy.